44 related articles for article (PubMed ID: 28181464)
21. Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy.
Gao Z; Li Z; Yan J; Wang P
Drug Des Devel Ther; 2017; 11():2595-2604. PubMed ID: 28919710
[TBL] [Abstract][Full Text] [Related]
22. Dual targeting of l-carnitine-conjugated nanoparticles to OCTN2 and ATB
Kou L; Yao Q; Sivaprakasam S; Luo Q; Sun Y; Fu Q; He Z; Sun J; Ganapathy V
Drug Deliv; 2017 Nov; 24(1):1338-1349. PubMed ID: 28911246
[TBL] [Abstract][Full Text] [Related]
23. Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.
Elgqvist J
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28531102
[TBL] [Abstract][Full Text] [Related]
24. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
Wang F; Li L; Liu B; Chen Z; Li C
Biomed Pharmacother; 2017 Feb; 86():595-604. PubMed ID: 28027535
[TBL] [Abstract][Full Text] [Related]
25. Combination of a chemopreventive agent and paclitaxel in CD44-targeted hybrid nanoparticles for breast cancer treatment.
Tran BN; Nguyen HT; Kim JO; Yong CS; Nguyen CN
Arch Pharm Res; 2017 Dec; 40(12):1420-1432. PubMed ID: 29027133
[TBL] [Abstract][Full Text] [Related]
26. Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake.
Luo Y; Teng Z; Li Y; Wang Q
Carbohydr Polym; 2015 May; 122():221-9. PubMed ID: 25817662
[TBL] [Abstract][Full Text] [Related]
27. Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment.
Yu D; Li W; Zhang Y; Zhang B
Biomed Pharmacother; 2016 Oct; 83():1428-1435. PubMed ID: 27592131
[TBL] [Abstract][Full Text] [Related]
28. New Folate-Grafted Chitosan Derivative To Improve Delivery of Paclitaxel-Loaded Solid Lipid Nanoparticles for Lung Tumor Therapy by Inhalation.
Rosière R; Van Woensel M; Gelbcke M; Mathieu V; Hecq J; Mathivet T; Vermeersch M; Van Antwerpen P; Amighi K; Wauthoz N
Mol Pharm; 2018 Mar; 15(3):899-910. PubMed ID: 29341619
[TBL] [Abstract][Full Text] [Related]
29. Physicochemical characterization of chitosan-hyaluronan-coated solid lipid nanoparticles for the targeted delivery of paclitaxel: a proof-of-concept study in breast cancer cells.
Campos J; Varas-Godoy M; Haidar ZS
Nanomedicine (Lond); 2017 Mar; 12(5):473-490. PubMed ID: 28181464
[TBL] [Abstract][Full Text] [Related]
30. Physicochemical characterization techniques for solid lipid nanoparticles: principles and limitations.
Kathe N; Henriksen B; Chauhan H
Drug Dev Ind Pharm; 2014 Dec; 40(12):1565-75. PubMed ID: 24766553
[TBL] [Abstract][Full Text] [Related]
31. A close collaboration of chitosan with lipid colloidal carriers for drug delivery applications.
Bugnicourt L; Ladavière C
J Control Release; 2017 Jun; 256():121-140. PubMed ID: 28414148
[TBL] [Abstract][Full Text] [Related]
32. Receptor-Mediated Targeting in Breast Cancer through Solid Lipid Nanoparticles and Its Mechanism.
Malik Z; Parveen R; Abass S; Irfan Dar M; Husain SA; Ahmad S
Curr Drug Metab; 2022; 23(10):800-817. PubMed ID: 35430962
[TBL] [Abstract][Full Text] [Related]
33. Plausible role of chitosan in drug and gene delivery against resistant breast cancer cells.
Nandgude T; Pagar R
Carbohydr Res; 2021 Aug; 506():108357. PubMed ID: 34146935
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
